Tiziana reports positive data from the clinical study of nasal administration with foralumab, its proprietary fully human anti-cd3 monoclonal antibody, in covid-19 patients in brazil

New york and london, feb. 02, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / lse: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reports positive data from the exploratory clinical study in brazil investigating nasally administered foralumab, its proprietary anti-cd3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone (“dexa”) in covid-19 patients. the clinical study was completed in collaboration with scientific teams at the harvard medical school (boston, usa), and intrials, a full-service latin american cro based in sÃo paulo, brazil.
TLSA Ratings Summary
TLSA Quant Ranking